KYNA analogue SZR72 modifies CFA-induced dural inflammation- regarding expression of pERK1/2 and IL-1β in the rat trigeminal ganglion
(2016) In Journal of Headache and Pain 17(1).- Abstract
Background: Neurogenic inflammation has for decades been considered an important part of migraine pathophysiology. In the present study, we asked the question if administration of a novel kynurenic acid analogue (SZR72), precursor of an excitotoxin antagonist and anti-inflammatory substance, can modify the neurogenic inflammatory response in the trigeminal ganglion. Methods: Inflammation in the trigeminal ganglion was induced by local dural application of Complete Freunds Adjuvant (CFA). Levels of phosphorylated MAP kinase pERK1/2 and IL-1β expression in V1 region of the trigeminal ganglion were investigated using immunohistochemistry and Western blot. Findings: Pretreatment with one dose of SZR72 abolished the CFA-induced pERK1/2 and... (More)
Background: Neurogenic inflammation has for decades been considered an important part of migraine pathophysiology. In the present study, we asked the question if administration of a novel kynurenic acid analogue (SZR72), precursor of an excitotoxin antagonist and anti-inflammatory substance, can modify the neurogenic inflammatory response in the trigeminal ganglion. Methods: Inflammation in the trigeminal ganglion was induced by local dural application of Complete Freunds Adjuvant (CFA). Levels of phosphorylated MAP kinase pERK1/2 and IL-1β expression in V1 region of the trigeminal ganglion were investigated using immunohistochemistry and Western blot. Findings: Pretreatment with one dose of SZR72 abolished the CFA-induced pERK1/2 and IL-1β activation in the trigeminal ganglion. No significant change was noted in case of repeated treatment with SZR72 as compared to a single dose. Conclusions: This is the first study that demonstrates that one dose of KYNA analog before application of CFA can give anti-inflammatory response in a model of trigeminal activation, opening a new line for further investigations regarding possible effects of KYNA derivates.
(Less)
- author
- Lukács, M. LU ; Warfvinge, K. LU ; Kruse, L. S. ; Tajti, J. ; Fülöp, F. ; Toldi, J. ; Vécsei, L. and Edvinsson, L. LU
- organization
- publishing date
- 2016-12-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Complete Freund’s Adjuvant, Dura mater, IL-1β, KYNA, pERK1/2, Trigeminal ganglion
- in
- Journal of Headache and Pain
- volume
- 17
- issue
- 1
- article number
- 64
- publisher
- Springer
- external identifiers
-
- pmid:27377707
- wos:000386608100002
- scopus:84977575572
- ISSN
- 1129-2369
- DOI
- 10.1186/s10194-016-0654-5
- language
- English
- LU publication?
- yes
- id
- a09d598e-2659-469d-941e-03cd661f081c
- date added to LUP
- 2016-10-12 13:22:06
- date last changed
- 2024-09-06 23:36:16
@article{a09d598e-2659-469d-941e-03cd661f081c, abstract = {{<p>Background: Neurogenic inflammation has for decades been considered an important part of migraine pathophysiology. In the present study, we asked the question if administration of a novel kynurenic acid analogue (SZR72), precursor of an excitotoxin antagonist and anti-inflammatory substance, can modify the neurogenic inflammatory response in the trigeminal ganglion. Methods: Inflammation in the trigeminal ganglion was induced by local dural application of Complete Freunds Adjuvant (CFA). Levels of phosphorylated MAP kinase pERK1/2 and IL-1β expression in V1 region of the trigeminal ganglion were investigated using immunohistochemistry and Western blot. Findings: Pretreatment with one dose of SZR72 abolished the CFA-induced pERK1/2 and IL-1β activation in the trigeminal ganglion. No significant change was noted in case of repeated treatment with SZR72 as compared to a single dose. Conclusions: This is the first study that demonstrates that one dose of KYNA analog before application of CFA can give anti-inflammatory response in a model of trigeminal activation, opening a new line for further investigations regarding possible effects of KYNA derivates.</p>}}, author = {{Lukács, M. and Warfvinge, K. and Kruse, L. S. and Tajti, J. and Fülöp, F. and Toldi, J. and Vécsei, L. and Edvinsson, L.}}, issn = {{1129-2369}}, keywords = {{Complete Freund’s Adjuvant; Dura mater; IL-1β; KYNA; pERK1/2; Trigeminal ganglion}}, language = {{eng}}, month = {{12}}, number = {{1}}, publisher = {{Springer}}, series = {{Journal of Headache and Pain}}, title = {{KYNA analogue SZR72 modifies CFA-induced dural inflammation- regarding expression of pERK1/2 and IL-1β in the rat trigeminal ganglion}}, url = {{http://dx.doi.org/10.1186/s10194-016-0654-5}}, doi = {{10.1186/s10194-016-0654-5}}, volume = {{17}}, year = {{2016}}, }